GlassScriptPhysician profile
Brooke Buchanan
NPI 1093350415
$5,718.75
in general payments reported to CMS, 2019-2025
26 companies · $55.36 in 2025
The $55.36 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $864 · 2022: $1,362 · 2023: $2,582 · 2024: $855 · 2025: $55.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,294 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.54 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $793.73 | 2021-2024 | Tremfya, Simponi, Simponi Aria |
| Merz North America, INC. | $776.01 | 2023 | Xeomin |
| Novartis Pharmaceuticals Corporation | $638.92 | 2021-2024 | |
| Galderma Laboratories, L.P. | $567.03 | 2021-2025 | Dysport, Aklief |
| Abbvie INC. | $519.73 | 2021-2024 | |
| Revance Therapeutics, INC. | $410.94 | 2024-2025 | Daxxify |
| Lilly USA, LLC | $391.74 | 2021-2024 | Taltz, Olumiant |
| Amgen INC. | $237.50 | 2021-2023 | Otezla |
| Pfizer INC. | $236.04 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $177.18 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $162.12 | 2021-2023 | Absorica Ld, Winlevi, Ilumya |
| Vyne Pharmaceuticals INC. | $161.95 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $104.64 | 2021-2023 | Libtayo |
| Genzyme Corporation | $93.28 | 2022-2023 | |
| Ucb, INC. | $61.73 | 2021-2024 | Bimzelx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $59.71 | 2022-2023 | Adbry |
| Incyte Corporation | $58.98 | 2023 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.57 | 2022-2024 | Spevigo |
| Journey Medical Corporation | $44.89 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.60 | 2022-2023 | Jublia, Arazlo |
| Biofrontera INC. | $38.22 | 2022 | |
| Epi Health, LLC | $24.40 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.62 | 2022 | |
| Nabriva Therapeutics, Plc | $14.67 | 2022 | |
| Arcutis Biotherapeutics, INC. | $13.82 | 2024 | Zoryve |
| Almirall LLC | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.